The Scottish Medicines Consortium (SMC) has advised NHS Boards and Area Drug and Therapeutic Committees that flecainide capsules (Tambocor XL®) are accepted for use in NHS Scotland for: the treatment of AV nodal reciprocating tachycardia, arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways; paroxysmal atrial fibrillation in patients with disabling symptoms when treatment need has been established and in the absence of left ventricular dysfunction.

The Committee adds that the capsules can be used for the maintenance of normal rhythm following conversion by other means, and patients for whom the use of flecainide is appropriate and who are controlled on 200mg daily using the immediate release formulation may be transferred to one 200mg XL capsule with the benefit of once-daily rather than twice-daily dosing at reduced cost.